Literature DB >> 23560023

Perioperative management of a hemophilia B infant with intracranial hemorrhage.

Sarika Juneja1, Pragati Ganjoo, Monica S Tandon, Ajay Sharma.   

Abstract

Entities:  

Year:  2012        PMID: 23560023      PMCID: PMC3611925          DOI: 10.4103/1817-1745.106494

Source DB:  PubMed          Journal:  J Pediatr Neurosci        ISSN: 1817-1745


× No keyword cloud information.
Dear Sir, A 2-month-old, 4.5 kg, infant was admitted with irritability, refusal of feeds, and seizures for 3 days with an altered sensorium, bulging anterior fontanel, right limb weakness, and pallor. There was no history of fever, trauma or drug use; his maternal grandfather had hemophilia B. Computed tomography of the head showed a left parietal subdural hematoma with the midline shift; cerebral angiography was normal. Hematology revealed a hemoglobin (Hb) of 4 g%, prolonged activated partial thromboplastin time (aPTT) of 120 (32.6) sec, low-plasma factor IX (FIX) activity of 4.3%, adequate platelets and normal bleeding, clotting and prothrombin times. Hemophilia B was diagnosed and 400 international units (IU) of FIX and 50 ml of packed red cells (PRC) were administered; his Hb and aPTT improved to 9.7 g% and 30/28 sec, respectively. Emergency craniotomy and hematoma evacuation was undertaken; 400 IU of FIX was repeated half-an-hour before surgery. The operation was meticulously performed to minimize surgical blood loss; extra care was taken to prevent bleeding and hematoma formation at non-operative sites that included, gentle oropharyngeal and tracheal suctioning, adequate pressure point padding and avoiding intramuscular injections. The child had an uneventful intraoperative course; blood loss averaged 50 ml and 50 ml PRC and 50 ml fresh frozen plasma (FFP) were transfused. Postoperatively, he was ventilated overnight and intubated uneventfully the following day; FIX (200 IU/day) was administered for two more weeks raising his plasma FIX activity to 60%. He improved neurologically and had no re-bleeding. Hemophilia B is an X-linked, recessive coagulation disorder secondary to deficiency or defect of FIX; it affects 1:25,000 males and accounts for 15% of all hemophilia cases. Patients with mild (FIX ~5-40%) and moderate disease (FIX ~1-5%) have excessive bleeding following minor trauma, while severe hemophiliacs (FIX < 1%) often manifest with spontaneous hemorrhages.[1] Intracranial hemorrhages (ICH) are known (incidence ~2.2-7.8%), and are among the commonest causes of death in hemophiliacs (mortality ~34%);[23] ICH may be the first manifestation of hemophilia,[24] also seen in our patient. Surgery for ICH in hemophiliacs is a high-risk procedure though use of perioperative clotting factor has markedly improved results.[5] Preoperative normalization of FIX activity up to 60-80%, and its postoperative maintenance to over 30% for at least 14 days is recommended.[1] Factor doses (IU) are calculated by the desired rise in factor activity (%) × body weight (kg), and once daily dose of FIX is adequate; monitoring is by FIX assays or serial aPTT (acceptable values ~patients’ aPTT/normal ≤1.2). Thus a safe surgical outcome in hemophiliacs with ICH is possible with perioperative clotting factor and FFP therapy besides the routine precautions.
  4 in total

Review 1.  Intracranial haemorrhage as initial presentation of severe haemophilia B: case report and review of Mayo Clinic Comprehensive Hemophilia Center experience.

Authors:  V Rodriguez; K A Schmidt; J A Slaby; R K Pruthi
Journal:  Haemophilia       Date:  2005-01       Impact factor: 4.287

Review 2.  Spontaneous intracranial hemorrhage as the presenting sign of hemophilia B in a 3-month-old infant.

Authors:  G R Gerlacher
Journal:  Pediatr Emerg Care       Date:  1999-12       Impact factor: 1.454

3.  Spontaneous subdural hematoma in a young adult with hemophilia.

Authors:  D Agrawal; A K Mahapatra
Journal:  Neurol India       Date:  2003-03       Impact factor: 2.117

Review 4.  Intracranial haemorrhage in haemophilia A and B.

Authors:  Rolf C R Ljung
Journal:  Br J Haematol       Date:  2007-12-13       Impact factor: 6.998

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.